CSC Wins $19.7 Million Award for Advanced Development of Biodefense Vaccines

EL SEGUNDO, Calif. -- Computer Sciences Corporation (CSC) announced that DVC LLC, a CSC company, has been awarded approximately $19.7 million in grants and contract modifications from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health.

The new grants and contract modifications are in addition to the award of an $11 million grant to CSC from the NIAID in September 2003.

Under the terms of these new awards, DVC will continue the advanced development of vaccines for tularemia, botulism and Venezuelan equine encephalitis.  The company will perform stability testing and manufacture a current good manufacturing practices pilot batch of live tularemia vaccine.  DVC also will conduct a phase 2 clinical trial for its Venezuelan equine encephalitis vaccine candidate and continue development of a stable multivalent botulinum vaccine candidate.

NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services.  NIAID conducts and supports research that strives to understand, treat and ultimately prevent the myriad of infectious, immunologic and allergic diseases that threaten hundreds of millions of people worldwide.

DVC is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines and therapeutics.  DVC is part of CSCs Enforcement, Security and Intelligence organization, which CSC created in 2002 to support programs enhancing U.S. security.

Source: Computer Sciences Corporation